RESTORE trial could turn NVG-291 into NervGen’s defining spinal cord injury asset

NervGen Pharma is approaching the most consequential clinical test in its history with a stronger financial and regulatory position than it had when the first NVG-291 spinal cord injury signals emerged. Site activation and patient screening for the Phase 3 RESTORE trial are expected to begin in September 2026, with the first participant anticipated to receive treatment shortly afterward. The approximately 150-patient study has already been shaped through an End-of-Phase 2 meeting with the United States Food and Drug Administration, while NervGen Pharma ended June with C$86.8 million, or about US$61.1 million, in cash and cash equivalents. Management expects that balance to fund operations through the anticipated RESTORE topline readout in the first half of 2028, placing the clinical outcome rather than an immediate financing requirement at the center of the investment case.

That combination considerably sharpens the risk-reward proposition around NVG-291. The Phase 1b/2a CONNECT SCI study produced a 3.3-point placebo-adjusted improvement in a validated measure of fine-motor hand function after 12 weeks, while subsequent independent biomechanical analyses added evidence that lower-body improvements may have reflected neurological recovery rather than simple compensation. Those results came from very small patient groups, however, and RESTORE must now demonstrate that the apparent benefit can survive expansion to roughly 150 adults treated across as many as 60 sites in the United States and Canada.

FDA alignment reduces trial-design uncertainty while concentrating risk on NVG-291 efficacy

RESTORE is designed as a randomized, double-blind and placebo-controlled Phase 3 registrational study in adults aged 18 to 75 with chronic cervical spinal cord injury at or above the C7 neurological level. Eligible participants must have American Spinal Injury Association Impairment Scale Grade C or D injuries and be between one and 10 years beyond the original trauma. Patients will receive once-daily subcutaneous NVG-291 or placebo for 12 weeks, followed by four weeks of observation and an optional 12-week open-label extension.

The primary endpoint is change at week 12 on the GRASSP Quantitative Prehension assessment, which measures functional hand use. Key secondary measures include patient and clinician impressions of improvement, independence in daily activities and lower-extremity spasticity, while blinded interviews are intended to determine whether numerical improvements translate into changes patients actually notice in daily life. The endpoint strategy matters commercially because improved hand and finger function can affect activities ranging from eating and dressing to using phones, computers and mobility equipment.

NervGen Pharma has already reached FDA alignment on these core study parameters, reducing the risk that a technically successful trial later proves poorly designed for regulatory purposes. That does not imply that one positive RESTORE result automatically guarantees approval, but it gives the company a more clearly defined route toward a marketing application than many small biotechnology companies possess before Phase 3 begins.

The chronic population creates both an advantage and a challenge. Meaningful spontaneous neurological recovery is generally expected to have substantially plateaued years after spinal cord injury, making new improvement potentially easier to attribute to treatment than it would be soon after trauma. The biological challenge is correspondingly greater because NervGen Pharma is attempting to stimulate neurological repair long after scar-associated inhibitory pathways have become established.

CONNECT SCI gives RESTORE a compelling benchmark but the patient numbers remain the biggest warning

The most important efficacy evidence comes from the chronic tetraplegia cohort of CONNECT SCI. NVG-291-treated participants improved by an average 3.7 points on GRASSP Quantitative Prehension at week 12 compared with 0.4 points for placebo, producing a 3.3-point treatment difference. NervGen Pharma said that difference exceeded the approximately two-point threshold regarded as minimally important for the measure.

The treatment effect also persisted after dosing ended. At week 16, four weeks after treatment cessation, the NVG-291 group showed a mean 4.4-point improvement compared with 1.2 points in the placebo group. Six of eight treated participants rated themselves as much or very much improved, compared with three of nine placebo recipients, providing an additional patient-reported indication that the measured hand-function changes may have been noticeable outside formal testing.

Those percentages look striking but illustrate why Phase 3 is essential. Eight treated patients and nine placebo patients are far too few to establish a dependable commercial effect size, and the outcome of only one or two participants can materially alter the apparent response rate. RESTORE therefore does not need merely to achieve statistical significance; it needs to show that the magnitude and consistency of improvement remain persuasive when the dataset becomes several times larger and spans numerous rehabilitation centers.

NervGen Pharma subsequently reported independent, blinded gait analyses that favored NVG-291 across coordination, mechanical effort and postural stability. A combined statistical analysis produced a significant treatment effect with a p-value of 0.0197, while all 10 evaluated NVG-291 patients met the analysis-defined responder criterion compared with one of 10 placebo patients. These results provide additional support for the neurorepair hypothesis, although RESTORE’s approval strategy remains anchored primarily in upper-extremity function rather than the gait analysis.

$60m financing gives NervGen room to reach the readout without an obvious emergency raise

NervGen Pharma substantially changed its financial position during the second quarter by completing a US$60 million underwritten public offering. Cash and cash equivalents subsequently stood at C$86.8 million, or US$61.1 million, at June 30 compared with C$22.1 million at the end of 2025. Management believes those resources are sufficient to fund operations through the anticipated RESTORE topline data in the first half of 2028.

That runway is important because RESTORE enrollment is expected to continue through the second half of 2027 before the company reaches the readout. A small biotechnology company entering Phase 3 with only a few quarters of cash could be forced to raise equity during enrollment, making shareholder dilution almost as important as clinical execution. NervGen Pharma has already raised much of the capital it expects to need to answer the central NVG-291 efficacy question.

Spending is nevertheless rising as the trial approaches. Second-quarter research and development expenses increased to C$7.9 million from C$2.7 million a year earlier, driven primarily by RESTORE start-up costs, clinical manufacturing and toxicology work. The company reported a quarterly net loss of C$29.2 million, although C$19.4 million resulted from a noncash unrealized loss associated with warrant derivatives and therefore does not represent the underlying cash cost of running the business.

NervGen Pharma also established an at-the-market equity facility allowing it to sell up to US$50 million of additional common shares. No shares had been sold through that program as of the August 13 update, meaning the facility currently provides financing flexibility rather than realized capital. Its existence nevertheless creates the possibility of additional dilution if costs increase, enrollment slows or management chooses to strengthen the balance sheet before the Phase 3 result.

NGEN shares show investors are waiting for Phase 3 evidence rather than another execution milestone

NervGen Pharma shares were trading at approximately $1.75 late on August 13, down about 0.6% from the previous close after moving between $1.71 and $1.80 during the session. The restrained reaction indicates that investors are treating the September screening timeline and second-quarter financial update primarily as execution milestones rather than reasons to materially revalue NVG-291 before RESTORE begins producing efficacy evidence. That interpretation is inferred from the trading pattern rather than confirmed by individual investors.

The market’s caution is understandable because the valuation argument still depends overwhelmingly on a single clinical proposition. NervGen Pharma now has FDA alignment, sufficient expected funding through the readout, a 150-patient registrational design and a previous randomized signal that exceeded the minimally important difference on its chosen Phase 3 endpoint. The remaining uncertainty is also the hardest one to eliminate: whether the surprisingly strong gains observed in fewer than 20 relevant participants represent a reproducible treatment effect.

A positive RESTORE study could materially change the company’s position because chronic tetraplegia remains an area where current care is focused heavily on rehabilitation, assistive technology and management of complications rather than an approved medicine demonstrated to restore lost neurological function. NVG-291 is designed to target the inhibitory CSPG-PTPσ pathway associated with the post-injury environment and thereby support neural repair and plasticity, giving the program a fundamentally restorative objective rather than a purely symptomatic one.

Failure would be equally consequential because NVG-291 remains the company’s central clinical asset and much of the recently raised capital is now being deployed around RESTORE. NervGen Pharma has substantially reduced financing and trial-design uncertainty, but those achievements cannot de-risk the fundamental biology. September screening therefore starts a roughly 18-month countdown toward the point when a small but compelling early study confronts the statistical demands of Phase 3.

Key takeaways on what the NVG-291 Phase 3 launch means for NervGen Pharma

• RESTORE patient screening is expected to begin in September 2026, with the first participant anticipated to receive NVG-291 shortly afterward.
• The randomized Phase 3 study will enroll approximately 150 adults with chronic tetraplegia across as many as 60 sites in the United States and Canada.
• FDA alignment has already been reached on the study population, dosing period, primary endpoint and other major elements of the registrational design.
• GRASSP Quantitative Prehension at week 12 will measure whether NVG-291 improves fine-motor hand function, a clinically important domain in tetraplegia.
• CONNECT SCI showed a 3.3-point placebo-adjusted advantage on the same hand-function measure, exceeding the company-cited two-point minimally important difference.
• The early efficacy dataset remains very small, making replication across approximately 150 patients the central clinical risk.
• NervGen Pharma raised US$60 million during the second quarter and held approximately US$61.1 million in cash at June 30.
• Management expects existing cash to fund operations through the anticipated RESTORE topline readout in the first half of 2028.
• NGEN shares traded near $1.75 on August 13, down about 0.6%, reflecting a relatively neutral market response ahead of actual Phase 3 enrollment and efficacy data.
• RESTORE now concentrates the NervGen Pharma investment case around one fundamental question: whether NVG-291 can reproduce its early neurological recovery signal in a registrational population.